Back to research

Research paper

Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders

Systematic derivation and validation of peripheral-blood methylation episignatures across 42 Mendelian NDDs including DNMT3A (TBRS), NSD1 (Sotos), EZH2 (Weaver), KMT2D (Kabuki 1), KDM6A, ATRX, CHD7/CHARGE, CHD8, and others. DNMT3A loss-of-function variants produce a robust characteristic hypomethylation episignature. Episignatures can diagnose patients with clinically suggestive phenotypes even when standard sequencing is negative.

Indexed context

Levy MA, Relator R, McConkey H, et al.

episignatureepisignmethylationchromatinopathydnmt3asotoskabuki

Markdown path

content/research/papers/2022-levy-episignatures-42-ndd.md

Findings

Systematic derivation and validation of peripheral-blood methylation episignatures across 42 Mendelian NDDs including DNMT3A (TBRS), NSD1 (Sotos), EZH2 (Weaver), KMT2D (Kabuki 1), KDM6A, ATRX, CHD7/CHARGE, CHD8, and others. DNMT3A loss-of-function variants produce a robust characteristic hypomethylation episignature. Episignatures can diagnose patients with clinically suggestive phenotypes even when standard sequencing is negative.

Why it may matter for Levi

Technical foundation for EpiSign / methylation panel as a functional diagnostic in Levi's case. Tests a different mechanism (genome-wide methylation state) than the three already-negative sequencing workups. A single panel covers DNMT3A, NSD1, EZH2, KMT2D, ATRX, and imprinting loci at once.

Paper text

Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders

Levy MA, Relator R, McConkey H, et al. — AJHG / PMC (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC7058829/

Findings summary

Systematic derivation and clinical validation of peripheral-blood DNA methylation episignatures across 42 Mendelian neurodevelopmental disorders, including multiple chromatinopathies and overgrowth syndromes relevant to Levi's differential: DNMT3A (TBRS), NSD1 (Sotos), EZH2 (Weaver), KMT2D (Kabuki 1), KDM6A (Kabuki 2), SETD1B, ATRX, CHD7 (CHARGE), CHD8, and several others. Key technical claims:

  • DNMT3A loss-of-function variants produce a robust, characteristic genome-wide hypomethylation episignature in blood — consistent with the known biology that DNMT3A is a "writer" DNA methyltransferase whose loss reduces CpG methylation.
  • The episignature platform is designed to both functionally validate variants of uncertain significance (VUS) and — importantly — diagnose patients with clinically suggestive phenotypes in whom standard sequencing has not identified a pathogenic coding variant.
  • Case Clin136 in this cohort illustrates the second use case: a patient clinically suspected of ATRX-related syndrome whose targeted sequencing and exome sequencing were both negative, and for whom the ATRX episignature was the only molecular diagnostic finding.

Relevance to Levi

This paper establishes the technical and clinical foundation for an EpiSign or equivalent methylation / episignature assay as a functional diagnostic test in Levi's case. Specifically:

  • Two negative germline trio workups (Stanford exome, GeneDx WGS) plus a targeted reanalysis have excluded coding-region variants in DNMT3A, NSD1, EZH2, and adjacent chromatinopathy genes. An episignature panel tests a different mechanism (actual genome-wide methylation state), which can be abnormal even when standard sequencing is uninformative.
  • DNMT3A episignature performance has been independently reported at 100% sensitivity (see van der Sanden 2023), making it one of the most reliable functional readouts in the episignature panel.
  • The methylation-first framing also covers BWS / 11p15, Sotos / 5q35 targeted methylation mechanisms, Kabuki, and other chromatinopathies with one blood draw, which is operationally efficient for a family that has already completed three exhaustive germline workups.

Provenance